Hims & Hers (HIMS) Q2 earnings 2025

Shares HIMS & HERS HERH After reporting the second quarter results that missed the Wall Street’s revenue expectations of Telehealth Company, it fell by 9% in expanded transaction on Monday.

The company made this based on the estimates of the average analysts compiled by LSEG:

• Earning per share: 17 cents set 15 cents
• Revenues: 544.8 million dollars and 552 million dollars

According to a statement, the income in HIMS & HERS increased by 73% of $ 315.6 million in the same period last year. Hims & Hers reported $ 42.5 million per share or 17 cents net income per share, compared to $ 13.3 million or 6 cents per share in the same period of the previous year.

For the third quarter, Hims & Hers expected to notify the income between $ 570 million and $ 590 million, while analysts were expecting $ 583 million. The company said FAVÖK, a quarter, will be between 60 million dollars and $ 70 million. Analysts who participated in the survey by Streetaccount were waiting for $ 77.1 million.

Hims & Hers has faced discussions in recent months about the sale of compound GLP-I, who have cheaper, unapproved versions of diabetes and weight loss drugs breaking box office records. Compound drugs can be produced when they are in brand treatments. problemHowever, the US Food and Drug Administration announced that the ongoing supply problems were solved in February.

Some Telealth companies, including HIMS & Herhari, continued to offer compound drugs. For example, a substance in a branded product, such as allergy, is legal for patients to access personalized doses in unique situations. HIMS & HERS said that consumers can still access personalized doses through their site if clinically applicable.

In June, HIMS & HERS shares rolled more than 30% after a short -lived cooperation. Novo Nordisk It was torn apart. The drug producer said that HIMS & HERS did not comply with the law that prohibits the mass sales of compound drugs under the “false guise of personalization”.

HIMS & HERS reported 82 million dollars of corrected FAVÖK in the second quarter of $ 39.3 million last year and expected by Streetaccount.

HIMS & HERS will organize its three -month call with investors in 17:00 ET.

Annika Kim Constantino from CNBC contributed to this report